1. Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma

3. Introduction

4. Introduction (cont)

5. Definition of Severe Asthma

6. Definition of Uncontrolled Asthma

7. Emerging Asthma Phenotypes

8. Goals of Asthma Management

9. Adults and Adolescents 12+ Years

10. What Is the Relationship of Blood Eosinophils to Severe Asthma Exacerbations?

11. Factors of Type 2 Inflammation

12. When to Consider Biologics?

13. Adverse Outcomes of Systemic Corticosteroids for Asthma

14. Why is it Important to Assess Inflammatory Phenotype on High-Dose ICS?

15. Adverse Outcomes from SCS: Long-Term Observational Study

16. Comorbidities as Part of the Severe Asthma Syndrome and OCS Side Effects

17. Factors to Predict Response to Biologics

18. Where Are We? Data From the UK General Population

19. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

20. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

21. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma (cont)

22. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

23. Targets for Biologic Treatments of T2-Type Asthma

24. T2 Status and Exacerbation Rate

25. When to Consider Biologics?

26. GINA Severe Asthma Options: Indications for Biologics

27. Annual Exacerbation Rate Ratio (Benralizumab vs Placebo)

28. Which Biologic is Appropriate to Start First?

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)